X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (238) 238
humans (228) 228
life sciences & biomedicine (227) 227
oncology (180) 180
male (132) 132
female (127) 127
melanoma (117) 117
middle aged (116) 116
aged (111) 111
adult (106) 106
melanoma - drug therapy (98) 98
melanoma - pathology (57) 57
treatment outcome (56) 56
melanoma - genetics (54) 54
mutation (53) 53
aged, 80 and over (52) 52
immunotherapy (47) 47
proto-oncogene proteins b-raf - genetics (43) 43
abridged index medicus (42) 42
antineoplastic agents - therapeutic use (39) 39
cancer (39) 39
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
skin neoplasms - drug therapy (37) 37
skin neoplasms - pathology (34) 34
disease-free survival (32) 32
care and treatment (29) 29
research (29) 29
animals (28) 28
antibodies, monoclonal - therapeutic use (27) 27
kidney neoplasms - drug therapy (27) 27
metastasis (27) 27
antineoplastic combined chemotherapy protocols - adverse effects (26) 26
carcinoma, renal cell - drug therapy (25) 25
dose-response relationship, drug (25) 25
immunology (25) 25
proto-oncogene proteins b-raf - antagonists & inhibitors (25) 25
antineoplastic agents - adverse effects (24) 24
melanoma - therapy (24) 24
skin neoplasms - genetics (24) 24
melanoma - mortality (23) 23
cell biology (22) 22
melanoma - immunology (22) 22
prognosis (22) 22
cell line, tumor (21) 21
health aspects (21) 21
interleukin-2 - administration & dosage (21) 21
neoplasms (21) 21
protein kinase inhibitors - therapeutic use (21) 21
antibodies, monoclonal - adverse effects (20) 20
clinical trials (20) 20
drug administration schedule (20) 20
drug therapy (20) 20
ipilimumab (20) 20
melanoma - secondary (20) 20
neoplasm staging (20) 20
vemurafenib (20) 20
general & internal medicine (19) 19
kaplan-meier estimate (19) 19
medicine, general & internal (19) 19
neoplasm metastasis (19) 19
nivolumab (19) 19
patients (19) 19
indoles - therapeutic use (18) 18
survival rate (18) 18
melanoma - metabolism (17) 17
neoplasms - drug therapy (17) 17
braf (16) 16
interleukin-2 - therapeutic use (16) 16
medicine, research & experimental (16) 16
metastases (16) 16
mice (16) 16
research & experimental medicine (16) 16
time factors (16) 16
tumors (16) 16
antineoplastic agents - administration & dosage (15) 15
chemotherapy (15) 15
follow-up studies (15) 15
genetic aspects (15) 15
interleukin-2 - adverse effects (15) 15
sulfonamides - therapeutic use (15) 15
young adult (15) 15
dermatology (14) 14
disease progression (14) 14
kidney neoplasms - pathology (14) 14
original reports (14) 14
survival analysis (14) 14
antineoplastic agents - pharmacology (13) 13
carcinoma, renal cell - mortality (13) 13
dacarbazine - administration & dosage (13) 13
dosage and administration (13) 13
gene mutations (13) 13
immunotherapy - methods (13) 13
indoles - adverse effects (13) 13
kidney neoplasms - mortality (13) 13
analysis (12) 12
antibodies, monoclonal - administration & dosage (12) 12
antineoplastic agents (12) 12
drug resistance, neoplasm (12) 12
medicine & public health (12) 12
nras (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 02/2012, Volume 366, Issue 8, pp. 707 - 714
Journal Article
The lancet oncology, ISSN 1470-2045, 03/2018, Volume 19, Issue 3, pp. 310 - 322
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2010, Volume 363, Issue 8, pp. 711 - 723
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 4, pp. 482 - 489
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 05/2013, Volume 31, Issue 14, pp. 1767 - 1774
Journal Article